Treatment of nonalcoholic fatty liver disease with total alkaloids in Rubus aleaefolius poir through regulation of fat metabolism

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  Li, Ying ^a,b   Zhao, Jinyan ^c   Zheng, Haiyin ^b   Zhong, Xiaoyong ^c   Zhou, Jianheng ^b   Hong, Zhenfeng ^c  

^a China Xiamen Hospital of Traditional Chinese Medicine   (China)

^b Jinshan Street Community Health Service ^*  (China)

^c FUJIAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ALKALOID; CARNITINE PALMITOYLTRANSFERASE; CHOLESTEROL; FATTY ACID SYNTHASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION; LIPID DIET; LIPID METABOLISM; MALE; METABOLIC REGULATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; RAT; RUBUS; RUBUS ALEAEFOLIUS POIR; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

EID: 84908267238     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/768540     Document Type: Article

References (26)

1. Clark J. M., Brancati F. L., Diehl A. M., Nonalcoholic fatty liver disease. Gastroenterology 2002 122 6 1649 1657 10.1053/gast.2002.33573 2-s2.0-0036090972
2. Matteoni C. A., Younossi Z. M., Gramlich T., Boparai N., McCullough A. J., Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999 116 6 1413 1419 10.1016/S0016-5085(99)70506-8 2-s2.0-0033038672
3. Brunt E. M., Janney C. G., Di Bisceglie A. M., Neuschwander-Tetri B. A., Bacon B. R., Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology 1999 94 9 2467 2474 10.1111/j.1572-0241.1999.01377.x 2-s2.0-0033200054
4. de Alwis N. M. W., Day C. P., Non-alcoholic fatty liver disease: the mist gradually clears. Journal of Hepatology 2008 48 S104 S112 10.1016/j.jhep.2008.01.009 2-s2.0-40849083460
5. Chen C.-H., Huang M.-H., Yang J.-C., Nien C.-K., Yang C.-C., Yeh Y.-H., Yueh S.-K., Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of Clinical Gastroenterology 2006 40 8 745 752 10.1097/00004836-200609000-00016 2-s2.0-33748457319
6. Bellentani S., Saccoccio G., Masutti F., Crocè L. S., Brandi G., Sasso F., Cristanini G., Tiribelli C., Prevalence of and risk factors for hepatic steatosis in Northern Italy. Annals of Internal Medicine 2000 132 2 112 117 2-s2.0-0033982172
7. Shen L., Fan J.-G., Shao Y., Zeng M.-D., Wang J.-R., Luo G.-H., Li J.-Q., Chen S.-Y., Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World Journal of Gastroenterology 2003 9 5 1106 1110 2-s2.0-0038544021
8. Angulo P., Nonalcoholic fatty liver disease. The New England Journal of Medicine 2002 346 1221 1231 10.1056/NEJMra011775
9. McCullough A. J., Update on nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology 2002 34 3 255 262 10.1097/00004836-200203000-00013 2-s2.0-0036176194
10. Saha A. K., Ruderman N. B., Malonyl-CoA and AMP-activated protein kinase: an expanding partnership. Molecular and Cellular Biochemistry 2003 253 1-2 65 70 10.1023/A:1026053302036 2-s2.0-0142181286
11. Ji H.-F., Li X.-J., Zhang H.-Y., Natural products and drug discovery. EMBO Reports 2009 10 3 194 200 10.1038/embor.2009.12 2-s2.0-61849148824
12. Shi K. Q., Fan Y. C., Liu W. Y., Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Molecular Biology Reports 2012 39 10 9715 9722 10.1007/s11033-012-1836-0
13. Hong Z.-F., Li T.-J., Zhao J.-Y., Effect of total alkaloids of Rubus alceaefolius poiron on gene expressions of CYP2E1 and CYP3A1 in rats with acute liver injury. Zhongguo Zhong Xi Yi Jie He Za Zhi 2009 29 8 711 715 2-s2.0-79955575880
14. Lin J., Zhao J., Li T., Zhou J., Hu J., Hong Z., Hepatoprotection in a rat model of acute liver damage through inhibition of CY2E1 activity by total alkaloids extracted from Rubus alceifolius poir. International Journal of Toxicology 2011 30 2 237 243 10.1177/1091581810390711 2-s2.0-79955613251
15. Bonkovsky H. L., Jawaid Q., Tortorelli K., LeClair P., Cobb J., Lambrecht R. W., Banner B. F., Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. Journal of Hepatology 1999 31 3 421 429 10.1016/S0168-8278(99)80032-4 2-s2.0-0033198317
16. Brunt E. M., Steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005 22 4 330 338 10.1053/j.semdp.2006.04.002 2-s2.0-33746383056
17. Postic C., Girard J., Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. Journal of Clinical Investigation 2008 118 3 829 838 10.1172/JCI34275 2-s2.0-40549135297
18. Angulo P., GI epidemiology: nonalcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2007 25 8 883 889 10.1111/j.1365-2036.2007.03246.x 2-s2.0-34547732002
19. Dixon J. B., Bhathal P. S., O'Brien P. E., Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001 121 1 91 100 10.1053/gast.2001.25540 2-s2.0-0034950652
20. Marchesini G., Brizi M., Blanchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001 50 8 1844 1850 10.2337/diabetes.50.8.1844 2-s2.0-0035431018
21. Saha A. K., Ruderman N. B., Malonyl-coa and AMP-activated protein kinase: an expanding partnership. Molecular and Cellular Biochemistry 2003 253 1-2 65 70 10.1023/A:1026053302036 2-s2.0-0142181286
22. Ruderman N., Prentki M., AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome. Nature Reviews Drug Discovery 2004 3 4 340 351 10.1038/nrd1344 2-s2.0-3843061592
23. Bartlett K., Eaton S., Mitochondrial β -oxidation. European Journal of Biochemistry 2004 271 3 462 469 10.1046/j.1432-1033.2003.03947.x 2-s2.0-0842287450
24. Cong W.-N., Tao R.-Y., Tian J.-Y., Liu G.-T., Ye F., The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice. Life Sciences 2008 82 19-20 983 990 10.1016/j.lfs.2008.01.022 2-s2.0-42649104331
25. Saggerson D., Malonyl-CoA, a key signaling molecule in mammalian cells. Annual Review of Nutrition 2008 28 253 272 10.1146/annurev.nutr.28.061807.155434 2-s2.0-50949087166
26. Cinti D. L., Cook L., Nagi M. N., Suneja S. K., The fatty acid chain elongation system of mammalian endoplasmic reticulum. Progress in Lipid Research 1992 31 1 1 51 10.1016/0163-7827(92)90014-A 2-s2.0-0026544667